Partnerships for Outsourcing eBook
BioPharm International’s Partnerships for Outsourcing eBook
Read the article:
Read the eBook:
CONTINUE TO SITE
OR WAIT null SECS
Advertisement
- About Us
- Advertise
- Editorial Information
- Contact Us
- Do Not Sell My Personal Information
- Privacy Policy
- Terms and Conditions
© 2024 MJH Life Sciences™ and BioPharm International. All rights reserved.
The CDMO Carousel
Published on:
Grant Playter
BioPharm International, BioPharm International, Partnerships for Outsourcing May 2022, Volume 2022 eBook, Issue 2
Pages: 32-35
Acquisitions in the CDMO space can give us insight into a company's vision for their future.
Actions speak louder than words, and in the highly competitive biopharmaceutical market large acquisitions are often the equivalent of shouting one’s intentions from the rooftops. In this vein, BioPharm International has collected the latest acquisition news from major contract, development, and manufacturing companies (CDMOs) in the hopes of providing insight into possible market movements.
Read this article in BioPharm International’s Partnerships for Outsourcing eBook.
Advertisement
References
- Merck KGaA, “Acquisition of Exelead Completed, Plans to Invest More Than € 500 Million in Technology Scale-Up,” Press Release, Feb. 23, 2022.
- Catalent, “Catalent Acquires Facility in Oxfordshire to Expand Biologics Capabilities in the UK and Across Europe,” Press Release, April 6, 2022.
- Recipharm, “Recipharm acquires GenIbet to bolster Biologics offering,” Press Release, Feb. 1, 2022.
- Recipharm, “Recipharm expands its advanced therapy medicinal products (ATMPs) offering into Virotherapies with the acquisition of Vibalogics,” Press Release, Feb. 18, 2022.
- Recipharm, “Recipharm Acquires Arranta Bio, a CDMO Leader in Advanced Therapy Medicinal Products (ATMPs), to Expand Its Niologics Offering in the US,” Press Release, Feb. 18, 2022.
- Samsung Biologics, “Samsung Biologics Reaches Agreement with Biogen to Acquire Full Ownership of Samsung Bioepis,” Press Release, Jan. 27, 2022.
- FDA, “FDA Approves First Interchangeable Biosimilar Insulin Product for Treatment of Diabetes,” Press Release, July 28, 2021.
- FDA, “FDA Approves Cyltezo, the First Interchangeable Biosimilar to Humira,” Press Release, Oct. 18, 2021.
- FDA, “FDA Approves First Biosimilar to Treat Macular Degeneration Disease and Other Eye Conditions,” Press Release, Sep. 17, 2021.
- ten23 health, “Launch of ten23 health – opening a new chapter in contract pharmaceutical development and manufacturing services,” Press Release, Sep. 1, 2021.
- ten23 health, “Swissfillon, a Leader in Sterile Filling of Complex Pharmaceuticals, Joins ten23 health and Enhances the Combined Company’s Integrated Offering to Its Customers,” Press Release, Oct. 25, 2021.
- Fujifilm Diosynth Biotechnologies, “Fujifilm Expands its Advanced Therapies CDMO Business with the Acquisition of a Dedicated Cell Therapy Manufacturing Facility from Atara Biotherapeutics, Inc.,” Press Release, Jan. 26, 2022.
- Fujifilm Diosynth Biotechnologies, “FUJIFILM Diosynth Biotechnologies Doubles its Existing Laboratory Footprint in North Carolina,” Press Release, Jan. 5, 2022.
About the author
Grant Playter is the Assistant Editor at Pharmaceutical Technology.
Article details
BioPharm International
eBook: Partnerships for Outsourcing
May 2022
Pages: 32-35
Citation
When referring to this article, please cite it as G. Playter, "The CDMO Carousel," BioPharm International’s Partnerships for Outsourcing eBook (May 2022).
